Free Trial

Akero Therapeutics 8/9/2024 Earnings Report

Akero Therapeutics logo
$28.37 -0.97 (-3.31%)
(As of 05:45 PM ET)

Akero Therapeutics EPS Results

Actual EPS
-$0.81
Consensus EPS
-$0.90
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Akero Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Akero Therapeutics Announcement Details

Quarter
Time
Before Market Opens
2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]

Akero Therapeutics Earnings Headlines

How Low-Cost Stocks Generate Monthly Income
Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!
Akero Therapeutics initiated with a Buy at Citi
Akero Therapeutics (AKRO) Receives a Buy from Phillip Securities
See More Akero Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Akero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akero Therapeutics and other key companies, straight to your email.

About Akero Therapeutics

Akero Therapeutics (NASDAQ:AKRO), together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

View Akero Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings